Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy

Drug Metabolism and Disposition

Volumn 26, Issue 9, 1998, Pages 883-890

  Aeschlimann, C ^a   Kupfer A ^b   Schefer, H ^b   Cerny, T ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IFOSFAMIDE; MESNA; METHYLENE BLUE;

ADULT; AGED; ARTICLE; BRAIN DISEASE; BRAIN PROTECTION; BRAIN TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG EFFECT; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIDOTES; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; EXPECTORANTS; FEMALE; HUMANS; IFOSFAMIDE; INJECTIONS, INTRAVENOUS; MALE; MESNA; METHYLENE BLUE; MIDDLE AGED;

EID: 0345020361     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Aeschlimann C, Cerny T and Küpfer A (1997) Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos 12:1336-1339.
2. Alonso JL, Nieto Y, Lopez JA, Martin M and Diaz-Rubio E (1996) Ifosfamide encephalopathy and methylene blue: A case report. Ann Oncol 7:643-645.
3. Boos J, Welslau U, Ritter J, Blaschke G and Schellong G (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28:455-460.
4. Castallanos AM and Fields WS (1986) Grading of neurotoxicity in cancer therapy (letter). J Clin Oncol 4:1277-1278.
5. Cerny T, Castiglione M, Brunner K, Küpfer A, Martinelli G and Lind M (1990) Ifosfamide by continous infusion to prevent encephalopathy. Lancet 335:175.
6. Cerny T and Küpfer A (1992) The enigma of ifosfamide encephalopathy. Ann Oncol 3:679-681.
7. Cerny T, Lind M, Thatcher N, Swinell R and Stout R (1989) A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC). Br J Cancer 60:258-261.
8. Cerny T, Margison JM, Thatcher N and Wilkinson PM (1986) Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol 18:261-264.
9. Demandt M and Wandt H (1996) Erfolgreiche Behandlung von Ifosfamid-bedingten zentralnervösen Nebenwirkungen mit Methylenblau. DMW (Dtsch Med Wochenschr) 121:575.
10. Ferrero JM, Eftekari P, Largillier R, Dreyfus G and Namer M (1995) Treatment of ifosfamide-induced encephalopathy with methylene blue (letter). Bull Cancer 82:598-599.
11. Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE and Zorsky PE (1995) Maximum-tolerated doses of ifosfamide, carboplatin and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 13:323-332.
12. Friedman OM and Boger E (1961) Colorimetric estimation of the nitrogen mustards in aqueous media. Anal Chem 33:906-910.
13. Goren MP, Wright RK, Pratt CB and Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet 331:1219-1220.
14. Highley MS, Momerency G, Van Cauwenberghe K, Van Oosterom AT, De Bruijn EA, Maes RAA, Blake P, Mansi J and Harper PG (1995) Formation of chloroethylamine and 1,3-oxazolidine-2-one. Drug Metab Dispos 23:433-437.
15. Kamen BA, Frenkel E and Colvin OM (1995) Ifosfamide: Should the honeymoon be over? J Clin Oncol 13:307-309.
16. Keizer JH, Ouwerkerk J, Welvaart K, van der Velde CJ and Cleton FJ (1995) Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 121:297-302.
17. Küpfer A, Aeschlimann C and Cerny T (1996) Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy (minireview). Eur J Clin Pharmacol 50:249-252.
18. Küpfer A, Aeschlimann C, Wermuth B and Cerny T (1994) Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 343:763-764.
19. Kurowski V, Cerny T, Küpfer A and Wagner T (1991) Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 117(suppl IV):S148-S153.
20. Kurowski V and Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36-42.
21. Kutscher B, Niemeyer U, Engel J, Kleemann A, Hilgard P, Pohl J and Scheffler G (1995) Synthesis and antitumor activity of two ifosfamide analogs with a five-membered ring. Arzneim Forsch 45:323-326.
22. Lewis LD, Fitzgerald DL, Harper PG and Rogers HJ (1990) Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 30:725-732.
23. Lind MJ, Margison JM, Cerny T, Thatcher N and Wilkinson PM (1989) Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 49:753-757.
24. Lind MJ, Roberts HL, Thatcher N and Idle JR (1990) The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26: 105-111.
25. Manegold C, Bischoff H, Fischer JR, Löchner S, Peukert M, Schmähl A and Drings P (1992) Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer. Ann Oncol 3:723-726.
26. McNeil NO and Morgan LR (1981) The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. Int J Clin Pharmacol Ther Toxicol 19:490-493.
27. Meanwell CA, Blake AE and Kelly KA (1986) Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 22:815-819.
28. Montmerency G and Van Cauwenberghe K (1994) Determination of iphosphamide and seven metabolites in blood plasma, as stable trifluoroacetyl derivatives by electron capture chemical ionization GC-MS. J High Resolut Chromatogr 17:655-661.
29. Neumann R, Hevey R and Abeles RH (1975) The action of plasma amine oxidase on beta-haloamines. J Biol Chem 250:6362-6367.
30. Pohl J, Bertram B, Hilgard P, Nowrousian MR, Stüben J and Wiessler M (1995) D-19575 - a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother Pharmacol 35:364-370.
31. Preussmann R, Schneider H and Epple F (1969) Untersuchungen zum Nachweis alkylierender Agentien. Der Nachweis verschiedener Klassen alkylierender Agentien mit einer Modifikation der Farbreaktion mit 4-(4′-Nitrobenzyl)-Pyridin. Arzneim Forsch 7:1059-1073.
32. Scheef W (1983) Psychotische Zustandsbilder im Verlauf der Ifosfamid-Therapie und Verhütung durch Piracetam (Nootrop). Muench Med Wochenschr 125:35-36.
33. Schlenzig JS, Charpentier C, Rabier D, Kamoun P, Sewell AC and Harpey JP (1995) L-Carnitine: a way to decrease cellular toxicity of ifosfamide? Eur J Pediatr 154:686-687.
34. Vincent M, Drings P, Burk K, Hermann R, Gluck S, Mitrou PS, van Zandwijk N, Schnaars Y, Bachmann P, Johnson W, Kocha W and Lopez P (1995) A phase II study of continuous oral ifosfamide (ifos) in advanced non-small cell lung cancer (abstract #1188). Proceedings of ASCO 14:382.
35. Wagner T and Drings P (1986) Pharmacokinetics and bioavailability of oral ifosfamide. Arzneim Forsch/Drug Res 36:878-880.
36. Wang JJH and Chan KK (1995) Identification of new metabolites of ifosfamide in rat urine using ion cluster technique. J Mass Spectrometry 30:675-683.
37. Zulian GB, Tullen E and Maton B (1995) Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med 332:1239-1240.